UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1175-10
Program Prior Authorization/Notification
Medication Cotellic® (cobimetinib)
P&T Approval Date 1/2016, 12/2016, 11/2017, 11/2018, 11/2019, 11/2020, 11/2021,
11/2022, 11/2023, 11/2024
Effective Date 2/15/2025
1. Background:
Cotellic (cobimetinib) is a kinase inhibitor indicated for the treatment of patients with
unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination
with Zelboraf® (vemurafenib) and as a single agent for the treatment of patients with histiocytic
neoplasms.1 The National Cancer Comprehensive Network (NCCN) also recommends the use of
Cotellic in combination with Zelboraf® (vemurafenib) as treatment for Central Nervous System
(CNS) Cancers.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Cotellic will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Melanoma
1. Initial Authorization
a. Cotellic will be approved based on all of the following criteria:
(1) Diagnosis of melanoma
-AND-
(2) One of the following:
© 2024 UnitedHealthcare Services, Inc.
1
(a) Patient has unacceptable toxicities to Tafinlar (dabrafenib) or Mekinist
(trametinib) on the basis of agent side-effect profile
-OR-
(b) Disease is one of the following:
i. Relapsed > 3 months after treatment discontinuation
ii. Unresectable
iii. Metastatic
-AND-
(3) Disease is positive for one of the following mutations:
(a) BRAF V600E
(b) BRAF V600K
-AND-
(4) Used in combination with Zelboraf (vemurafenib)
Authorization will be issued for 12 months.
2. Reauthorization
a. Cotellic will be approved based on both of the following criteria:
(1) Patient does not show evidence of progressive disease while on Cotellic therapy
-AND-
(2) Used in combination with Zelboraf (vemurafenib)
Authorization will be issued for 12 months.
C. Central Nervous System (CNS) Cancers
1. Initial Authorization
a. Cotellic will be approved based on all of the following criteria:
(1) Diagnosis of one of the following:
(a) Circumscribed glioma
(b) Glioblastoma
(c) Limited brain metastases
© 2024 UnitedHealthcare Services, Inc.
2
(d) Extensive brain metastases
-AND-
(2) Disease is BRAF V600E positive
-AND-
(3) Used in combination with Zelboraf (vemurafenib)
Authorization will be issued for 12 months.
2. Reauthorization
a. Cotellic will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Cotellic therapy
-AND-
(2) Used in combination with Zelboraf (vemurafenib)
Authorization will be issued for 12 months.
D. Histiocytic Neoplasms
1. Initial Authorization
a. Cotellic will be approved based on the following criterion:
(1) Diagnosis of one of the following histiocytic neoplasms:
(a) Langerhans cell histiocytosis
(b) Erdheim-Chester disease
Authorization will be issued for 12 months.
2. Reauthorization
a. Cotellic will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Cotellic
therapy.
Authorization will be issued for 12 months.
E. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
© 2024 UnitedHealthcare Services, Inc.
3
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Cotellic [package insert]. Genentech USA, Inc.: South San Francisco, CA; May 2023.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
http://www.nccn.org. Accessed September 25, 2024.
Program Prior Authorization/Notification – Cotellic (cobimetinib)
Change Control
1/2016 New program.
12/2016 Annual Review. Added criteria to use in combination with Zelboraf.
Updated references.
11/2017 Annual Review. Updated references.
11/2018 Annual review. Added coverage for CNS cancers per NCCN
guidelines. Updated background and references.
11/2019 Annual review. Added in combination with Zelboraf (vemurafenib) to
continuation therapy. Added NCCN recommended regimens criteria.
Updated references.
11/2020 Annual review. Updated background to match coverage criteria. No
change in coverage criteria. Updated references.
11/2021 Annual review. Updates per NCCN recommendations to CNS cancer
and histiocytic neoplasms. Updated reference.
11/2022 Annual review. Updated CNS cancer criteria removing BRAF V600K
to align with NCCN recommendations. Added state mandate footnote.
Updated references.
11/2023 Annual review. Updated histiocytic neoplasms criteria based on labeled
indication and CNS cancer based on NCCN recommendations.
Updated background and references.
11/2024 Annual review. Updated melanoma, central nervous system cancers,
© 2024 UnitedHealthcare Services, Inc.
4
and histiocytic neoplasms criteria based on NCCN guidelines.
© 2024 UnitedHealthcare Services, Inc.
5